Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 10;19(1):14.
doi: 10.1186/s12886-019-1027-z.

Long-term results of glaucoma drainage device surgery

Affiliations

Long-term results of glaucoma drainage device surgery

Konstantine Purtskhvanidze et al. BMC Ophthalmol. .

Abstract

Background: To evaluate long-term results of eyes with glaucoma drainage device (GDD).

Methods: We retrospectively reviewed medical records of all patients who underwent GDD placement at our institution between 2001 and 2014. A total of 110 eyes of 90 patients were studied. Glaucoma outcome was assessed by postoperative intraocular pressure (IOP), number of medications, and need for further glaucoma surgery. Surgical procedures before and during the study period, and their complications were evaluated.

Results: The mean follow-up was 78.3 ± 44.0 months. The mean preoperative intraocular pressure was 30.8 ± 6.9 mmHg with 3.5 ± 1.1 glaucoma medications. At last postoperative follow-up, the mean IOP decreased to 14.3 ± 5.4 mmHg with 1.6 ± 1.5 glaucoma medications. GDD implantation successfully controlled glaucoma in 86, 85, 81, 78, 79, 76 and 73% of eyes at 1, 2, 3, 4, 5, 7 and 10 years, respectively. At last follow-up IOP was successfully controlled in 67% of eyes. Clinical complications occurred in 56.4% of eyes during the follow-up period.

Conclusions: A glaucoma drainage device can successfully control intractable glaucoma even after a very long period of time.

Keywords: Ahmed valve; Baerveldt implant; Glaucoma drainage device; Glaucoma surgery; IOP control.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study adhered to the tenets of the Declaration of Helsinki. For this retrospective type of study formal consent is not required according the regulations of the IRB Universitiy Medical Center Schleswig-Holstein.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival analysis of IOP (intraocular pressure)
Fig. 2
Fig. 2
Overall Kaplan-Meier survival analysis of glaucoma success throughout follow-up
Fig. 3
Fig. 3
Kaplan-Meier survival analysis of corneal clarity throughout follow-up

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267. doi: 10.1136/bjo.2005.081224. - DOI - PMC - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713. doi: 10.1001/archopht.120.6.701. - DOI - PubMed
    1. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, et al. Predictors of long-term progression in the early manifest glaucoma treatment trial. Ophthalmology. 2007;114:1965–1972. doi: 10.1016/j.ophtha.2007.03.016. - DOI - PubMed
    1. Gedde SJ, Singh K, Schiffman JC, Feuer WJ. Tube versus trabeculectomy study group. The tube versus trabeculectomy study: interpretation of results and application to clinical practice. Curr Opin Ophthalmol. 2012;23:118–126. doi: 10.1097/ICU.0b013e32834ff2d1. - DOI - PubMed
    1. Schwartz KS, Lee RK, Gedde SJ. Glaucoma drainage implants: a critical comparison of types. Curr Opin Ophthalmol. 2006;17:181–189. doi: 10.1097/01.icu.0000193080.55240.7e. - DOI - PubMed

MeSH terms

Substances